Proglucagon, the precursor of glucagon, contains within its sequence two peptide domains related in structure to glucagon. One of these glucagon-like peptides, GLP-I is liberated from proglucagon in the intestinal L cells and the pancreatic islets. The synthetic peptide GLP-I(7-37) has potent insulinotropic actions on pancreatic beta cells at concentrations as low as 10- 11M. The long range goals of this project are to define the role that the newly discovered GLP-I(7-37) peptide has in the regulation of insulin secretion and glucose homeostasis and to determine whether GLP-I(7-37) contributes to the impairment of the beta- cell response to glucose observed in non-insulin dependent diabetes mellitus. The immediate goal is to study the nature of the inteactions of GLP-I(7-37) with the beta-cell. The first part of the project will be an analysis of (i) the binding of GLP-I(7-37) to specific receptor(s) and (ii) the manner in which the binding of GLP-(7-37) is coupled to increases in cellular levels of cAMP. For this purpose we will utilize insulin secreting cell- lines. We will also explore the relative contributions of GLP-I(7- 37) and glucagon to the insulinotropic effect. In particular, we wish to determine whether glucagon acts on the beta-cell in the capacity of an agonist of GLP-I(7-37). In the second part of the project, we will investigate the structural requirements that are necessary for the expression of the biological action of GLP-I(7-37) on beta cells. A selected number of GLP-I(7-37) analogs will be synthesized by the method of solid phase peptide synthesis and their biological potencies measured using both the insulin secreting cell-lines and perfused pancreas preparation. These studies have potential implications for obtaining an understanding of the pathogenesis of non-insulin dependent diabetes mellitus.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rockefeller University
Other Domestic Higher Education
New York
United States
Zip Code